Dr. Richard Clarkson from Cardiff University's European Cancer Stem Cell Research Institute and Dr. Andrea Brancale and Dr. Andrew Westwell from the Cardiff University School of Pharmacy and Pharmaceutical Sciences announced the discovery of a drug candidate that has proven to reduce the spread of breast cancer in mice by as much as 80 percent at the Cardiff University website on Jan. 26, 2014.
The researchers investigated a drug that would fit the molecular shape of the B-cell lymphoma 3-encoded protein (BCL3) gene that has been proven to be a major factor in the spread of breast cancer within the breast and to other organs.
A computer program provided a survey or presently known drugs that would fit the BCL3 gene molecular structure and deactivate the gene. The program provided one drug that inhibited the ability of the BCL3 gene to produce the spread of breast cancer.
Trials of the drug in mice produced an 80 percent rate of reduction in the spread of breast cancer. The drug was also found to completely inhibit the development of tumor cells that could spread to other parts of the body.
Human trials are planned in the hopes of producing similar results in the early development of breast cancer and particularly in the late stages of breast cancer that have few effective treatment options at present.